Management of choroidal neovascularization in pathologic myopia: Combined therapy
Yıl: 2010 Cilt: 18 Sayı: 3 Sayfa Aralığı: 197 - 202 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Management of choroidal neovascularization in pathologic myopia: Combined therapy
Öz: Amaç: Patolojik myopiye bağlı koroidal neovaskülarizasyonda (KNV) verteporfinli fotodinamik tedavi (FDT) ve intravitreal bevacizumab (İVB) kombinasyon tedavisinin sonuçlarının bildirilmesi.Gereç ve Yöntem: Patolojik myopiye bağlı KNV nedeniyle FDT ve 2.5 mg İVB tedavisi alan hastaların kayıtları retrospektif olarak incelendi. Gözlerin tümü tedaviden önce ve sonra Snellen görme keskinliği değerlendirmesi (GK) ve tam oftalmolojik muayeneye ek olarak optik koherens tomografi ve floresein anjiografi ile değerlendirildi. Bütün kontrol vizitlerinde her lezyona bir aktivite skoru (AS) verildi. Kontrol vizitlerinde AS’nin en az 7 olması durumunda tekrar tedavi uygulandı.Bulgular: Çalışmaya toplam 6 hasta dahil edildi. LogMAR GK tedaviden önce 1.30 iken, son kontrolde 0.86 idi (p<0.05). GK’de ortalama 2 (-2-4) Snellen sırası artış izlendi. AS her kontrolde başlangıçtaki değere gore anlamlı olarak düşük bulundu (p<0.05). Başlangıç fovea kalınlığı 394.4±222.7 μm iken son takipteki fovea kalınlığı 175.4±25.4 μm idi (p<0.05). Ortalama 28 aylık takip süresi sonunda ortalama FDT/hasta sayısı 1.7 iken İVB sayısı 2.5 idi. Tartışma: Bu çalışmanın sonuçlarına gore myopik KNV tedavisinde FDT ve İVB kombinasyon tedavisi hem tekrar tedavi ihtiyacını azaltarak hem de görme keskinliğinde artış sağlayarak, etkili bir tedavi seçeneği gibi görülmektedir.
Anahtar Kelime: Konular:
Patolojik miyopiye bağlı koroidal neovaskülarizasyonda kombinasyon tedavisi
Öz: Purpose: To report the outcome of combined verteporfin photodynamic therapy (PDT) and intravitreal bevacizumab (IVB) for the treatment of choroidal neovascularization (CNV) due to pathologic myopia.Materials and Methods: The reports of the patients with CNV secondary to pathologic myopia who received PDT and 2.5 mg of IVB were reviewed. All of the eyes were examined with optic coherence tomography and fluorescein anjiography in addition to Snellen visual acuity (VA) assessment and total ophthalmologic examination both before and after treatment. An activity score (AS) was given to each lesion during all visits. Retreatments were done if the AS is at least 7 during the control visits.Results: Six patients were included. The mean logMAR VA was 1.30 before treatment, 0.86 at the last visit (p<0.05). Mean improvement in VA was 2 (range, -2 to 4) Snellen lines. The mean AS was significantly lower than the baseline at each visit (p<0.05). Initial foveal thickness improved from 394.4±222.7 μm to 175.4±25.4 μm after the last follow-up (p<0.05). The mean number of PDT/patient was 1.7 and that of IVB was 2.5 during the 28 months of a mean follow-up.Conclusion: The results of this study suggest that PDT combined with IVB seems to be effective in treating myopic CNV by reducing retreatment needs and improving visual acuity.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik
- 1. Hotchkiss ML, Fine SL.: Pathologic myopia and choroidal neovascularization. Am J Ophthalmol. 1981;91:177-183.
- 2. Cohen SY, Laroche A, Leguen Y, et al.: Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241-1244.
- 3. Ohno-Matsui K, Yoshida T, Futagami S, et al.: Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathological myopia. Br J Ophthalmol. 2003;87:570-573.
- 4. Secrétan M, Kuhn D, Soubrane G, et al.: Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997;7:307-316
- 5. Verteporfin in Photodynamic Therapy Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology. 2001;108:841-852.
- 6. Blinder KJ, Blumenkranz MS, Bressler NM, et al.: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology. 2003;110:667-673.
- 7. Gelisken F, Inhoffen W, Hermann A, et al.: Verteporfin photodynamic therapy for extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2004;242:926-930.
- 8. Lam DS, Liu DT, Fan DS, et al.: Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series. Eye. 2005;19:834-840.
- 9. Schnurrbusch UE, Jochmann C, Wiedemann P, et al.: Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2005;243:829-833.
- 10. Rosenfeld PJ, Moshfeghi AA, Puliafito CA.: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
- 11. Avery RL, Pieramici DJ, Rabena MD, et al.: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
- 12. Emerson MV, Lauer AK, Flaxel CJ, et al.: Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27:439-444.
- 13. Yamamoto I, Rogers AH, Reichel E, et al.: Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br J Ophthalmol. 2007;91:157-160.
- 14. Sakaguchi H, Ikuno Y, Gomi F, et al.: Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol. 2007;91:161-165.
- 15. Chan WM, Lai TY, Liu DT, et al.: Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology. 2007;114:2190-2196.
- 16. Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al.: Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina. 2007;27:707-712.
- 17. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al.: Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye. 2009;23:334-338.
- 18. Ikuno Y, Sayanagi K, Soga K, et al.: Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009;147:94-100.
- 19. Gharbiya M, Allievi F, Mazzeo L, et al.: Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. 2009;147:84-93.
- 20. Chan WM, Lai TY, Wong AL, et al.: Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularization secondary to pathological myopia: a pilot study. Br J Ophthalmol. 2007;91:174-179.
- 21. Lazic R, Gabric N.: Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245:68-73.
- 22. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25:119-134
- 23. Ozdek S, Hondur A, Gurelik G, et al.: Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV. Int Ophthalmol. 2005;26:127-133.
- 24. Ozdek S.: My way of assessment of neovascular AMD activity. When to treat? When to stop? Ophthalmol Times Europe, May 2009; e-pub, http://www.oteurope.com/ophthalmologytimeseurope// article/articledetail.jsp?ts=111809040229&id=598240
- 25. Lazic R, Gabric N.: Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007;114:1179-1185.
- 26. Dhalla MS, Shah GK, Blinder KJ, et al.. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006;26:988-993.
- 27. Han DP, McAllister JT, Weinberg DV, et al.: Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. Eye (Lond) 2009 Jun 5.
| APA | ÖZDEK Ş, ŞEKERYAPAN GEDİZ B, EKİCİ F, HASANREİSOĞLU B (2010). Management of choroidal neovascularization in pathologic myopia: Combined therapy. , 197 - 202. |
| Chicago | ÖZDEK Şengül,ŞEKERYAPAN GEDİZ BERRAK,EKİCİ Feyzahan,HASANREİSOĞLU Berati Management of choroidal neovascularization in pathologic myopia: Combined therapy. (2010): 197 - 202. |
| MLA | ÖZDEK Şengül,ŞEKERYAPAN GEDİZ BERRAK,EKİCİ Feyzahan,HASANREİSOĞLU Berati Management of choroidal neovascularization in pathologic myopia: Combined therapy. , 2010, ss.197 - 202. |
| AMA | ÖZDEK Ş,ŞEKERYAPAN GEDİZ B,EKİCİ F,HASANREİSOĞLU B Management of choroidal neovascularization in pathologic myopia: Combined therapy. . 2010; 197 - 202. |
| Vancouver | ÖZDEK Ş,ŞEKERYAPAN GEDİZ B,EKİCİ F,HASANREİSOĞLU B Management of choroidal neovascularization in pathologic myopia: Combined therapy. . 2010; 197 - 202. |
| IEEE | ÖZDEK Ş,ŞEKERYAPAN GEDİZ B,EKİCİ F,HASANREİSOĞLU B "Management of choroidal neovascularization in pathologic myopia: Combined therapy." , ss.197 - 202, 2010. |
| ISNAD | ÖZDEK, Şengül vd. "Management of choroidal neovascularization in pathologic myopia: Combined therapy". (2010), 197-202. |
| APA | ÖZDEK Ş, ŞEKERYAPAN GEDİZ B, EKİCİ F, HASANREİSOĞLU B (2010). Management of choroidal neovascularization in pathologic myopia: Combined therapy. Retina-Vitreus, 18(3), 197 - 202. |
| Chicago | ÖZDEK Şengül,ŞEKERYAPAN GEDİZ BERRAK,EKİCİ Feyzahan,HASANREİSOĞLU Berati Management of choroidal neovascularization in pathologic myopia: Combined therapy. Retina-Vitreus 18, no.3 (2010): 197 - 202. |
| MLA | ÖZDEK Şengül,ŞEKERYAPAN GEDİZ BERRAK,EKİCİ Feyzahan,HASANREİSOĞLU Berati Management of choroidal neovascularization in pathologic myopia: Combined therapy. Retina-Vitreus, vol.18, no.3, 2010, ss.197 - 202. |
| AMA | ÖZDEK Ş,ŞEKERYAPAN GEDİZ B,EKİCİ F,HASANREİSOĞLU B Management of choroidal neovascularization in pathologic myopia: Combined therapy. Retina-Vitreus. 2010; 18(3): 197 - 202. |
| Vancouver | ÖZDEK Ş,ŞEKERYAPAN GEDİZ B,EKİCİ F,HASANREİSOĞLU B Management of choroidal neovascularization in pathologic myopia: Combined therapy. Retina-Vitreus. 2010; 18(3): 197 - 202. |
| IEEE | ÖZDEK Ş,ŞEKERYAPAN GEDİZ B,EKİCİ F,HASANREİSOĞLU B "Management of choroidal neovascularization in pathologic myopia: Combined therapy." Retina-Vitreus, 18, ss.197 - 202, 2010. |
| ISNAD | ÖZDEK, Şengül vd. "Management of choroidal neovascularization in pathologic myopia: Combined therapy". Retina-Vitreus 18/3 (2010), 197-202. |
